tbuckley/cabot-search huggingface dataset:
Rituximab, Age and High Dose Therapy Followed By Autologus Stem Cell Transplantation Are Independent Prognostic Factors for Survival in the First Line Treatment of Primary CNS-Lymphoma
Authors: Michael Madle, Isabelle Herth, Nicola Lehners, Mark-Alexander Schwarzbich, Patrick Wuchter, Gerlinde Egerer, Anthony D. Ho, Mathias Witzens-Harig
Journal: Blood (2014)
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
Authors: Laura Cicconi, Uwe Platzbecker, Giuseppe Avvisati, Francesca Paoloni, Christian Thiede, Marco Vignetti, Paola Fazi, Felicetto Ferrara, Mariadomenica Divona, Francesco Albano, Fabio Efficace, Marco Sborgia, Eros Di Bona, Massimo Breccia, Erika Borlenghi, Roberto Cairoli, Alessandro Rambaldi, Lorella Melillo, Giorgio La Nasa, Walter Fiedler, Peter Brossart, Bernd Hertenstein, Helmut R. Salih, Ombretta Annibali, Mohammed Wattad, Michael Lubbert, Christian H. Brandts, Mathias Hanel, Christoph Rollig, Norbert Schmitz, Hartmut Link, Chiara Frairia, Claudio Fozza, Alfonso Maria D’Arco, Nicola Di Renzo, Agostino Cortelezzi, Francesco Fabbiano, Konstanze Dohner, Arnold Ganser, Hartmut Dohner, Sergio Amadori, Franco Mandelli, Maria Teresa Voso, Gerhard Ehninger, Richard F. Schlenk, Francesco Lo-Coco
Journal: Leukemia (2019)
Risk Factors and Clinical Impact of Chronic Kidney Disease (CKD) after Allogeneic Stem Cell Transplant (allo-SCT)
Authors: Hiroaki Shimizu, Takuma Ishizaki, Nahoko Hatsumi, Satoru Takada, Akihiko Yokohama, Takayuki Saitoh, Yoshihisa Nojima, Hiroshi Handa
Journal: Blood (2016)
Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02
Authors: Xavier Leleu, Michel Attal, Philippe Moreau, Alain Duhamel, Jean Paul Fermand, Mauricette Michalet, Catherine Traulle, Gerald Marit, Murielle Roussel, Brigitte Kolb, Bertrand Arnulf, Laurent Garderet, Claire Mathiot, Margaret Macro, Marie Odile Petillon, Brigitte Pegourie, Anne Marie Stoppa, Sabine Brechiniac, Bruno Royer, Lotfi Benboubker, Denis Caillot, Martine Escoffre-Barbe, Cyrille Hulin, Jean-Luc Harousseau, Hervé Avet-Loiseau, Thierry Facon
Journal: Blood (2010)
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study
Authors: Andy Rawstron, Claudia Fazi, Neus Villamor, Julio Delgado, Remi Letestu, Florence Cymbalista, Carlos Palacio, Francesc Bosch, Ruth M De Tute, Stuart Liptrot, David O'Brien, Martin Spacek, Johan Dobber, Arnon P. Kater, Peter C Gambell, David A Westerman, Asha Soosapilla, Stephen P. Mulligan, Gerard Lozanski, Ke Lin, Andrew R Pettitt, Gabi Brachtl, Alexander Egle, David W Williamson, Catherine M Sanders, Harlan Robins, Justin Boysen, Tait D. Shanafelt, Curtis A. Hanson, Jeffrey L. Jorgensen, William G. Wierda, Constance Yuan, Maryalice Stetler-Stevenson, Laura Rassenti, H. Elizabeth Broome, Thomas J. Kipps, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, Nomdedeu Josep, Carol Moreno, Olga Stehlikova, Michael Doubek, Sarka Pospisilova, Karl-Anton Kreuzer, Michael Hallek, Peter Hillmen, Emili Montserrat, Paolo Ghia
Journal: Blood (2014)
Risk of Recurrent Venous Thromboembolism and Major Bleeding in Cancer-Associated Incidental Pulmonary Embolism Amongst Treated and Untreated Patients: A Pooled Analysis of 926 Patients
Authors: T van der Hulle, P L den Exter, G Meyer, B Planquette, S Soler, M Monreal, D Jimenez, A K Portillo, C O'Connell, H Liebman, M Shteinberg, Y Adir, M Tiseo, M Bersanelli, H N Abdel-Razeq, A H Mansour, O G Donnelly, G Radhakrishna, S Ramasamy, G Bozas, A Maraveyas, A B Shinagare, H Hatabu, M Nishino, M V Huisman, F A Klok
Journal: Blood (2014)
High Grade Non-Hodgkin’s Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.
Authors: Cyrille Touzeau, Pascaline Talmant, Anne Moreau, Richard Garand, Herve Avet-Loiseau, Nadine Juge-Morineau, Thomas Gastinne, Philippe Moreau, Jean-Luc Harousseau, Steven Le Gouill
Journal: Blood (2006)
Standardizing the classification of skin tears: validity and reliability testing of the International Skin Tear Advisory Panel Classification System in 44 countries
Authors: H. Van Tiggelen, K. LeBlanc, K. Campbell, K. Woo, S. Baranoski, Y.Y. Chang, A.M. Dunk, M. Gloeckner, H. Hevia, S. Holloway, P. Idensohn, A. Karadağ, E. Koren, J. Kottner, D. Langemo, K. Ousey, A. Pokorná, M. Romanelli, V.L.C.G. Santos, S. Smet, G. Tariq, K. Van den Bussche, A. Van Hecke, S. Verhaeghe, H. Vuagnat, A. Williams, D. Beeckman
Journal: British Journal of Dermatology (2019)

Skin tears are acute wounds that are frequently misdiagnosed and under-reported. A standardized and globally adopted skin tear classification system with supporting evidence for diagnostic validity and reliability is required to allow assessment and reporting in a consistent way.
Graft Versus Host Disease-Like Syndrome after Autologous Stem Cell Transplantation in CLL Patients Treated with a TBI/Cy/Alemtuzumab (CAMPATH-1H) High-Dose Regimen.
Authors: Thorsten Zenz, Peter Dreger, Alexander Kröber, Matthias Ritgen, Donald Bunjes, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2005)
Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution
Authors: Herve Ghesquieres, Celine Segura-Ferlay, Gaelle Fossard, Francois Ducray, Violaine Safar, Philippe Rey, Emmanuelle Nicolas-Virelizier, Catherine Sebban, Amine Belhabri, Pierre Biron, Emmanuel Jouanneau, David Meyronnet, Catherine Chassagne-Clement, Jerome Honnorat, Jean-Yves Blay
Journal: Blood (2015)
Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)
Authors: Changxia Shao, Jinan Liu, Wei Zhou, Monika Kumar Raut, Matthew Monberg, Xiting Cao, Alejandro Daniel Ricart, Arun Balakumaran
Journal: Blood (2016)
Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib
Authors: Leo WK Cheung, Karl J. Schweighofer, Shiquan Wu, Hsu-Ping Kuo, Karl Eckert, Sriram Balasubramanian, Deborah Ricci, Yu Liang, Darrin Beaupre, Betty Y. Chang
Journal: Blood (2015)
Contrasting the Long-Term Outcome of Reduced-Intensity Allogeneic Stem Cell Transplantation From Related Matched and Mismatched or Unrelated Matched Donor
Authors: Hui-Sheng Ai, Xiao-Jun Huang, Zhen-Hua Qiao, Jian-Min Wang, Ying-Min Liang, De-Pei Wu, Bao-An Chen, Hai Bai, Bao-Fu Shi, Wan-Jun Sun, He Huang
Journal: Blood (2011)
Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma
Authors: Silvia Locatelli, Arianna Giacomini, Anna Guidetti, Loredana Cleris, Michele Magni, Massimo Di Nicola, Roberta Mortarini, Alessandro M Gianni, Andrea Anichini, Carmelo Carlo-Stella
Journal: Blood (2011)
Non-p53 Dependent, Leukemia Initiating-Cell Selective, Therapy.
Authors: Kwok Peng Ng, Soledad Negrotto, Zhenbo Hu, Kevin A Link, Santosh L Saraf, Anjali Advani, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, James C. Mulloy, Yogenthiran Saunthararajah
Journal: Blood (2009)
Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.
Authors: Makiko Ban-Hoefen, Ann Vanderplas, Jennifer L. Kelly, Allison Crosby-Thompson, Gregory A. Abel, Myron S. Czuczman, Leo I. Gordon, Mark S. Kaminski, Michael Millenson, Auayporn Nademanee, Maria A. Rodriguez, Andrew D. Zelenetz, Joyce Niland, Ann LaCasce, Jonathan W. Friedberg
Journal: Blood (2012)
Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Authors: Annie Guerin, Cindy Revol, Agnihotram V. Ramanakumar, Rebekah Foster, Eric Qiong Wu, Shivani K Mhatre, Lei Chen
Journal: Blood (2014)
Determining value of high cost cancer therapies and discussing cost of cancer care: The patient perspective.
Authors: Saurabh Rajguru, Lakeesha Carmichael, Jeremy Paul Cetnar
Journal: Journal of Clinical Oncology (2013)

6512 Background: A trend in cancer treatment is the growing number of high-priced therapies which offer marginal clinical benefits. This has led ASCO to issue guidelines stressing the importance of discussing treatment costs with patients. There are many identified barriers which limit communication of cost including oncologists’ fears that patients may view this discussion as inappropriate. We attempted to assess cancer patients’ views on discussion of treatment costs with their oncologists, as well as, their views on high-cost drugs (HCDs), including the belief that there is a cohort of patients who would forgo high-priced treatment even if there was no out-of-pocket expense. Methods: We surveyed patients with advanced prostate cancer. The survey consisted of demographic information and an 11-item questionnaire. We also gave them a hypothetical scenario in which they were asked how much they would be willing-to-pay (WTP) for a $100K drug that would improve survival on average by four months with minimal side-effects (modeled after Provenge). The survey was administered to patients in clinic prior to their visit. Results: Of the patients approached, 169 responded (88% response rate). Seventeen percent stated they would not want treatment with HCDs even if they had no out-of-pocket expenses (more likely to be older (&gt;70) and have an annual household income of &gt;$60K). Another 21% stated they would accept treatment only if they had no out-of-pocket expenses. The median WTP for the hypothetical drug was $20K. Most patients (79%) agree that a discussion of costs with their physician is appropriate and 69% would want to have this discussion. Most patients (82%) agree that prognosis is important when making treatment decisions however 66% of patients did not know their cancer stage. Only 37% agree that the oncologist or the patient should consider the country’s healthcare costs when making treatment decisions. Conclusions: Prostate cancer patients clearly want to have discussions regarding costs-of-care with their oncologists. There is a group who would forgo treatment with high-cost drugs that yield only modest survival benefits. Their motivation is unknown, but is hypothesized to reflect a value-based judgment.
NIH-Defined Graft-Versus-Host Disease in Patients with Acute Lymphoblastic Leukemia: Natural History, Prognostic Impact and Effect of Donor Lymphocyte Infusions
Authors: Theis H. Terwey, Tanja M. Le Duc, Philipp G. Hemmati, Lam G. Vuong, Peter Martus, Philipp D. le Coutre, Bernd Dörken, Renate Arnold
Journal: Blood (2011)
Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2
Authors: Sheng-Xiao Zhang, Jia Wang, He-Hua Sun, Jia-Qian Zhang, Guang-Ying Liu, Jing Luo, Pei-Feng He, Xiao-Feng Li
Journal: Annals of the Rheumatic Diseases (2019)

We note with interest and express our principle agreement with the views put forward by Professor Rosenzwajg M1 in the recent Editorial ‘Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial’ published in Annals of the Rheumatic Diseases . The authors conclude that any autoimmune or inflammatory disease denotes a regulatory T cells (Tregs) insufficiency, which is restored by low-dose interleukin (IL)−2 ((1 million IU/day) for 5 days, followed by fortnightly injections for 6 months) selectively and safely activate and expand Tregs in 11 autoimmune diseases. This study is important and deserves a practical value. In our study, the absolute changes of peripheral lymphocyte subpopulations and CD4+ T subsets, especially Tregs, and the safety and efficacy of low-dose IL-2 in dermatomyositis (DM)/polymyositis (PM), which are idiopathic inflammatory myopathies and not shown in the above article, are shared with the readers.

In our study, total 147 patients with PM/DM were enrolled and 128 gender-matched and age-matched healthy adults were participated as controls from February 2016 to October 2018. The absolute numbers of T, B, natural killer (NK), CD4+ T, CD8+ T, Th1, Th2, Th17 and Tregs in peripheral blood of these individuals were detected by flow cytometry combined with standard absolute counting beads. …
IKZF1 (Ikaros) Deletions Are a Hallmark of BCR-ABL1 Positive Acute Lymphoblastic Leukemia.
Authors: Charles G. Mullighan, Christopher B. Miller, Letha A. Phillips, James Dalton, Jing Ma, Ina Radtke, Deborah White, Timothy P. Hughes, Michelle M. Le Beau, Sheila A. Shurtleff, James R. Downing
Journal: Blood (2007)
Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT
Authors: Norbert Claude Gorin, Myriam Labopin, Tomasz Czerw, Kurt Leibundgut, Didier Blaise, Pierre Yves Dumas, Damir Nemet, William Arcese, Roberto Foa, Wu Depei, Anne Huynh, Tsila Zuckerman, Ellen Meijer, Seckin Cagirgan, Jan Cornelissen, Mohamad Mohty, Arnon Nagler
Journal: Blood (2015)
Upregulation of Human Pim-2 in B-CLL, Involves Interactions between Oct-1, Oct-2, Bob-1 and NF-kB.
Authors: Yosef Dicken, Amos M. Cohen, Hanna Bessler, Daphna Levi-Hirsh, Ariela Arad, Drorit Merkel, Jeremy Don
Journal: Blood (2004)
Successful Treatment of Animal Models of Acute Graft-Versus-Host Disease with Small-Molecule TNF Inhibitor
Authors: Haiyan Gong, Yigeng Cao, Peng Liu, Haiyan Zhu, Zhezhe Wang, Fei Xiang, Tong Wang, Sizhou Feng, Mingzhe Han, Hongbo R. Luo, Jiaxi Zhou, Yuanfu Xu
Journal: Blood (2016)
Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody
Authors: Christina Krupka, Anna Jansen, Irène Lassmann, Jon Terrett, Dee Aud, Rachel Dusek, Arnima Bisht, Esteban Pombo-Villar, Christian Rohlff, Thomas Köhnke, Felix S Lichtenegger, Torben Altmann, Klaus H Metzeler, Michael Fiegl, Karsten Spiekermann, Wolfgang Hiddemann, Marion Subklewe
Journal: Blood (2014)
Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or –intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party
Authors: Jeong-Ok Lee, Inho Kim, Joo-Seop Chung, Yeo-Kyeoung Kim, Ho-Young Yhim, Dae-Young Kim, Young-Rok Do, Chu-Myong Seong, Seung-Hyun Nam, Sung-Hyun Kim, Jae-Hoon Lee, Jinny Park, Jin Seok Kim, Yoo-Hong Min, Sang Kyun Sohn, Young Don Joo, Sung-Hwa Bae, Sukjoong Oh, Dae Young Zang, Hong Ghi Lee, Sung-Soo Yoon, Seonyang Park
Journal: Blood (2012)
Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial
Authors: Marek Trneny, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John A Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon A. Rule, Boris V Afanasyev, Kamil Kaplanov, Antoine Thyss, Alexej Kuzmin, Sergey Voloshin, Kazimierz Kuliczkowski, Agnieszka Giza, Noel Milpied, Caterina Stelitano, Reinhard Marks, Lorenz Trümper, Tsvetan Biyukov, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Luca Arcaini
Journal: Blood (2016)
5q Deletions Can Be Identified Based on the Expression Level of 5q Genes: A Study on 49 Cases with MDS or AML Analysed in Parallel by Gene Expression Profiling and Genomic Arrays.
Authors: Claudia Schoch, Sonja Rauhut, Susanne Schnittger, Frank Dicker, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2006)
Antiproliferative Activity of ELACYT™ (CP-4055) in Combination with Cloretazine (VNP40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells.
Authors: David J. Adams, Marit L. Sandvold, Fynn Myhren, Tove F. Jacobsen, David A. Rizzieri
Journal: Blood (2006)
Using surgical and oncology workload to plan brain tumour trial recruitment in England
Authors: Kerlann Le Calvez, Peter Treasure, Matt Williams
Journal: Neuro-Oncology (2019)

Abstract Introduction Access to clinical trials is a common request for patients with brain tumours. However, opening clinical trials requires additional work per centre opened. We have previously shown that surgical and oncology workload varies between centres, and fluctuates over time. There is a trade-off between offering access to clinical trials and increasing costs associated with opening trials in centres that treat few patients. Methods We used two separate datasets from England covering 3 years – one for neurosurgical workload and one for radiotherapy. We only included adult patients and calculated cumulative proportions of the malignant primary brain tumour population (C71) by number of centres. We investigated stability by checking how many patients would have to be added/ removed from a centre to change their rank. Results There were 7061 surgical and 5060 radiotherapy patients. To capture 25% of patients, we would need to open trials in 4 surgical/5 radiotherapy centres; for 50%, 9 surgical/ 13 radiotherapy centres; for 75%, 16 surgical/ 24 radiotherapy centres. Centre rank was fluid: adding 16 surgical/9 radiotherapy patients would change the rank of a centre. Discussion These are the first data to allow for rational planning of trials in brain tumour patients. We have shown that we can reach 75% of the brain tumour population by opening trials in ~50% of surgical and radiotherapy centres. Centre rank alters over year, so we should be cautious about being too prescriptive. Nonetheless, these data should allow some rational planning of trial centre inclusion.
Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination
Authors: María-Victoria Mateos, Norma C. Gutierrez, Bruno Paiva, Albert Oriol, Joaquín Martínez-López, Ana Isabel Teruel, Raquel de Paz, Jose Garcia-Laraña, Enrique Bengoechea, Alejandro Martín, Joaquín Díaz-Mediavilla, Luis Palomera, Yolanda Gonzalez, Jose Mariano Hernández, Ana Sureda, Jose Luis Bello, Joan Bargay, Francisco-Javier Penalver, Josep-Maria Ribera, María-Luisa Martín-Mateos, Ramón García-Sanz, María Teresa Cibeira, María-Luisa Martín-Ramos, María-Belén Vidriales, María-Angeles Montalbán, Juan-Jose Lahuerta, Joan Blade, Jesús F. San Miguel
Journal: Blood (2010)
Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunoescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia
Authors: Henning Fedders, Ameera Alsadeq, Britt-Sabina Petersen, Christian Kellner, Matthias Peipp, Thomas Valerius, Robert Haesler, Julia Alten, Anja Möricke, Susanne Strube, Thomas Wiesel, Gunnar Cario, Martin Schrappe, Andre Franke, Martin Stanulla, Denis Martin Schewe
Journal: Blood (2014)
Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL).
Authors: Shih-Hsiang Chen, Deqing Pei, Wenjian Yang, Cheng Cheng, Sima Jeha, William E. Evans, Ching-Hon Pui, Mary V. Relling
Journal: Blood (2009)
Peripheral T cell lymphoma not otherwise specified induced by fingolimod treatment for multiple sclerosis
Authors: Hidetsugu Kawai, Hiromichi Matsushita, Hibiki Akashi, Shohei Kawakami, Daisuke Furuya, Rikio Suzuki, Yoshiaki Ogawa, Hiroshi Kawada, Naoya Nakamura, Kiyoshi Ando
Journal: Annals of Oncology (2019)
MEIS1 Induces a Megakaryocyte-Erythroid Fate by Upregulation of FOG1 and GATA1 Expression.
Authors: Sabrina Zeddies, Sjoert B.G. Jansen, Sylvia Nuernberg, Summa di Franca, Willem H Ouwehand, Jaap Jan Zwaginga, Mattia Frontini, Marieke von Lindern, Augosto Rendon, Ellen C.E. van der Schoot, Daphne C Thijssen-Timmer
Journal: Blood (2012)
Clonal Evolution of Gene Mutations in AML Transformation from Patients with De Novo Myelodysplastic Syndromes Carrying Spliceosome Mutations: An Analysis of 71 Paired Samples
Authors: Ming-Chung Kuo, Po-Nan Wang, Po Dunn, Tung-Liang Lin, Jin-Hou Wu, Tzung-Chih Tang, Yi-Jung Wu, Tung-Huei Lin, Chia-Hui Chang, Ting-Yu Huang, Che-Wei Ou, Der-Cherng Liang, Lee-Yung Shih
Journal: Blood (2016)
Daily Light and Darkness Signals Regulate Bone Marrow Stem Cell Development and Leukocyte Production Via Tnfα and an Interplay Between Norepinephrine and Melatonin
Authors: Karin Golan, Anju Kumari, Eman Khatib-Massalha, Sylwia Rzeszotek, Shiri Gur-Cohen, Zulma S. Ferreira, Tomer Itkin, Orit Kollet, Mariusz Z Ratajczak, Regina P. Markus, Tsvee Lapidot
Journal: Blood (2016)
Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma.
Authors: Mohamed Sorror, B. Storer, A. Gopal, L. Holmberg, B.M. Sandmaier, W.I. Bensinger, D.G. Maloney, O.W. Press, R.F. Storb
Journal: Blood (2007)
The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP
Authors: Barbara Botto, Domenico Novero, Annalisa Chiappella, Mattia Novo, Alessia Castellino, Chiara Ciochetto, Giovanni Cametti, Andrea Evangelista, Roberto Freilone, Paola Ghione, Marco Ladetto, Paola Riccomagno, Federico Vittone, Giovannino Ciccone, Umberto Vitolo
Journal: Blood (2014)
Efficacy and Safety of Rituximab in Common Variable Immunodeficiency-Associated Immune Cytopenias: a Retrospective Analysis of 10 Cases.
Authors: Delphine Gobert, Lionel Galicier, Alice Berezne, Christophe Auzary, Thierry de Revel, Felipe Suarez, Bernard Bonnotte, Roland Jaussaud, Marc Ruivard, Bertrand Godeau, Olivier Hermine, Marc Michel
Journal: Blood (2009)
The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance
Authors: Qunling Zhang, Juan J Gu, Cory Mavis, Ye Guo, Matthew J. Barth, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2016)
A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial)
Authors: Tiziano Barbui, Monia Lunghi, Alessia Tieghi, Guido Finazzi, Roberto Latagliata, Valerio De Stefano, Rossella Cacciola, Caterina Musolino, Marco Ruggeri, Emilio Usala, Giorgina Specchia, Elisa Rumi, Maria Luigia Randi, Alessandra Iurlo, Alessandro M. Vannucchi, Davide Rapezzi, Anna Rita Scortechini, Francesca Lunghi, Maria Carmen Martorelli, Daniela Cilloni, Michele Nobile, Sergio Siragusa, Simone Santini, Elena Elli, Giuseppe Visani, Giovanni Quarta, Antonio Spadea, Rosa Maria Marfisi, Arianna Masciulli, Roberto Marchioli
Journal: Blood (2012)
Antitumor Activity of MLN9708, a Second-Generation Proteasome Inhibitor, in Preclinical Models of Lymphoma.
Authors: Jill Donelan, Bret Bannerman, Kristen Bano, Trisha Babcock, Paul Hales, Bradley Stringer, Kristine Burke, Hadi Danaee, Laura Faron-Yowe, Erik Koenig, David Lichter, Erik Kupperman
Journal: Blood (2009)
90Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma
Authors: Katarina Luptakova, Michelle Kim, Pamela Ely, Barbara Grant, John Anthony Parker, Dimitrios Tzachanis, Jacalyn Rosenblatt, James Levine, David Avigan, Robin Joyce
Journal: Blood (2010)
Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.
Authors: Teresa Calimeri, Mariateresa Fulciniti, Jianhong Lin, Mehmet Kemal Samur, Anne S. Calkins, Ankit V Vahia, Jagannath Pal, Michele Cea, Antonia Cagnetta, Francesca Cottini, Sophia Adamia, AbdelKareem Azab, Stephane Minvielle, Hervé Avet-Loiseau, Cheng Li, Jean-Bernard Lazaro, Kenneth C. Anderson, Pierfrancesco Tassone, Masood A Shammas, Nikhil C. Munshi
Journal: Blood (2012)